Ionis Pharmaceuticals, Inc. (IONS)Healthcare | Biotechnology | Carlsbad, United States | NasdaqGS
56.75 USD
-1.50
(-2.575%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:33 a.m. EDT
The immediate outlook is defined by a brutal capitulation event followed by a fragile recovery attempt. The stock recently plunged nearly 32% in a single session, wiping out previous gains and leaving the price significantly below its 50-day moving average. While the recent 14-day price action shows a tentative bounce, the heavy volume on the downside suggests the selling pressure was not fully exhausted. Fundamentally, the picture remains precarious: the company is burning cash with negative operating margins and a forward P/E that implies no earnings visibility. The balance sheet is strained with debt exceeding cash, and the lack of a dividend confirms this is a pure growth/speculative play. Analyst targets remain elevated relative to the current price, creating a disconnect between the market's current pessimism and the consensus view of potential upside. For now, the risk-reward profile leans toward caution; the stock is in a defensive posture, waiting for a definitive clinical or commercial catalyst to justify a return to its higher valuation tiers. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.046075 |
| AutoETS | 0.052852 |
| AutoARIMA | 0.052853 |
| AutoTheta | 0.060526 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 2.76 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.003 |
| Excess Kurtosis | 0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 531.048 |
| Revenue per Share | 6.55 |
| Market Cap | 9,378,650,112 |
| Forward P/E | -58.73 |
| Beta | 0.37 |
| Profit Margins | -30.90% |
| Website | https://www.ionis.com |
As of July 11, 2026, 3:33 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional breakout. Call volume is heavily skewed toward out-of-the-money strikes (80, 85, 87.5), suggesting a speculative hope for a recovery to previous highs. However, put volume is even more aggressive, particularly in the near term (July/August) at strikes 55 and 60, indicating a strong hedge against further downside. The massive open interest walls at 80/85 for calls and 72.5/75 for puts suggest traders are betting on a wide range of outcomes, likely waiting for a catalyst like FDA approval results or partnership news to resolve the uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.36897767 |
| Address1 | 2,855 Gazelle Court |
| All Time High | 86.74 |
| All Time Low | 2.5 |
| Ask | 61.11 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 5,142,180 |
| Average Daily Volume3 Month | 2,358,449 |
| Average Volume | 2,358,449 |
| Average Volume10Days | 5,142,180 |
| Beta | 0.365 |
| Bid | 52.64 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 2.962 |
| City | Carlsbad |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 56.75 |
| Current Ratio | 4.098 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 57.91 |
| Day Low | 56.11 |
| Debt To Equity | 531.048 |
| Display Name | Ionis Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,465,800 |
| Earnings Call Timestamp Start | 1,777,465,800 |
| Earnings Timestamp | 1,777,465,800 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -338,648,992 |
| Ebitda Margins | -0.32002997 |
| Enterprise To Ebitda | -29.562 |
| Enterprise To Revenue | 9.461 |
| Enterprise Value | 10,011,231,232 |
| Eps Current Year | -2.61375 |
| Eps Forward | -0.96625 |
| Eps Trailing Twelve Months | -2.01 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 75.664 |
| Fifty Day Average Change | -18.914001 |
| Fifty Day Average Change Percent | -0.24997358 |
| Fifty Two Week Change Percent | 36.897766 |
| Fifty Two Week High | 86.74 |
| Fifty Two Week High Change | -29.989998 |
| Fifty Two Week High Change Percent | -0.3457459 |
| Fifty Two Week Low | 40.03 |
| Fifty Two Week Low Change | 16.720001 |
| Fifty Two Week Low Change Percent | 0.4176868 |
| Fifty Two Week Range | 40.03 - 86.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 674,487,000,000 |
| Float Shares | 163,966,898 |
| Forward Eps | -0.96625 |
| Forward P E | -58.732212 |
| Free Cashflow | -807,796,352 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,402 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.10936 |
| Gross Profits | 115,728,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0060799997 |
| Held Percent Institutions | 1.0731701 |
| Implied Shares Outstanding | 165,262,556 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California. |
| Long Name | Ionis Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 9,378,650,112 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_30300 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -326,976,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,626,543,887 |
| Number Of Analyst Opinions | 22 |
| Open | 57.91 |
| Operating Cashflow | -910,627,008 |
| Operating Margins | -0.47716 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 27.33 |
| Phone | 760 931 9200 |
| Pre Market Change | 0.049999237 |
| Pre Market Change Percent | 0.08810438 |
| Pre Market Price | 56.8 |
| Pre Market Time | 1,784,022,258 |
| Previous Close | 58.25 |
| Price Eps Current Year | -21.7121 |
| Price Hint | 2 |
| Price To Book | 19.159353 |
| Price To Sales Trailing12 Months | 8.862917 |
| Profit Margins | -0.309 |
| Quick Ratio | 2.862 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.65217 |
| Region | US |
| Regular Market Change | -1.5 |
| Regular Market Change Percent | -2.57511 |
| Regular Market Day High | 57.91 |
| Regular Market Day Low | 56.11 |
| Regular Market Day Range | 56.11 - 57.91 |
| Regular Market Open | 57.91 |
| Regular Market Previous Close | 58.25 |
| Regular Market Price | 56.75 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 5,096,098 |
| Return On Assets | -0.070300005 |
| Return On Equity | -0.67617 |
| Revenue Growth | 0.87 |
| Revenue Per Share | 6.55 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 165,262,556 |
| Shares Percent Shares Out | 0.105399996 |
| Shares Short | 17,425,020 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 16,986,466 |
| Short Name | Ionis Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1399 |
| Short Ratio | 8.59 |
| Source Interval | 15 |
| State | CA |
| Symbol | IONS |
| Target High Price | 125.0 |
| Target Low Price | 68.0 |
| Target Mean Price | 93.22727 |
| Target Median Price | 93.0 |
| Total Cash | 1,977,063,040 |
| Total Cash Per Share | 11.963 |
| Total Debt | 2,609,644,032 |
| Total Revenue | 1,058,190,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.01 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 76.09925 |
| Two Hundred Day Average Change | -19.34925 |
| Two Hundred Day Average Change Percent | -0.25426334 |
| Type Disp | Equity |
| Volume | 5,096,098 |
| Website | https://www.ionis.com |
| Zip | 92,010 |